Bonjour, new guests from small-town India
Puneet Dhawan of Accor is brimming with ideas on ways to revive the hospitality sector
Even as India became the first country to give two Covid-19 vaccines the go-ahead for restricted use in emergency situations, public health experts and politicians raised concerns on the lack of transparency involving these decisions.
There is no transparency when it comes to the granular details on the trials and their efficacy, said S Srinivasan, co-convenor with the All India Drug Action Network (AIDAN). If the AstraZeneca-Oxford University vaccine has 70.42 per cent efficacy, as the Drugs Controller General of India (DCGI) says, that data should be made public for technical people to be able to review, he told BusinessLine. Serum Institute has a production and marketing alliance for the AstraZeneca-Oxford University vaccine in India.
The approval for Bharat Biotech’s vaccine came in for sharp criticism from vaccine expert Gagandeep Kang, who told a business channel she was unaware of any efficacy data on the candidate. Kang is Professor, The Wellcome Trust Research Laboratory, CMC-Vellore.
Also seeking clarification on the efficacy of the vaccine were Congress leaders Jairam Ramesh and Shashi Tharoor, who pointed out that the vaccine is still going through advanced Phase III trials.
AIDAN further raised concerns on whether data from Indian participants in the local trial were submitted for the review of the AZ-Oxford University vaccine.
“The very objective of a bridging study to assess the vaccine candidate in an Indian population is lost if the data are not reviewed in the process of regulatory approval,” it said. How was the equivalence established between Serum Institute’s vaccine and that of AZ-Oxford University, it asked.
Further, Srinivasan said it is unclear under what provisions in the law the authorisation was given.
In Bharat Biotech’s case, the permission given in “clinical trial mode” has raised the hackles of many in the scientific community. “So, if something goes wrong, will the volunteer get compensation as outlined in laws governing clinical trials? And what about the compensation provision if such a case arises in the post-licensure period, for both vaccines?” Srinivasan asked.
While AIIMS Director Randeep Guleria was seen explaining that Bharat Biotech’s vaccine is a back-up, and the Serum Institute vaccine will be rolled out first, Kang observed that there appears to be no distinction in the approvals given to the two vaccines.
She also appeared doubtful of the vaccine’s use against the mutant UK strain.
Puneet Dhawan of Accor is brimming with ideas on ways to revive the hospitality sector
Citroen’s first vehicle sports a novel design and European interiors. It is also meant to be as comfortable as ...
The pandemic is only the tip of the iceberg that the country’s cash-poor airlines — both regional and national ...
The government is yet to specify the framework of its recently announced old vehicle scrappage policy
This Women’s Day, we discuss the features of a few financial products that aim to help you save, get insured ...
Sensex, Nifty 50 make a strong bounce-back, but test resistances
Avenue Supermarts (₹3,286.1): Makes fresh all-time highIn October last year, the stock of Avenue Supermarts ...
The exchange-traded fund ticks all boxes as an efficient tool to track gold prices
A cop, a poet, a wedding planner, an outraged wife: On International Women’s Day, a look at diverse stories ...
India’s privacy law must balance the rights of children with online safety
Muriel has put our names down on a list to get the Covid-19 vaccination because — hurrah! — the age limit has ...
They are the health warriors who battled the Covid-19 pandemic on the ground, and are now the face of the ...
Comfort, convenience, value, safety — and not necessarily the colour pink — but do brands deliver?
Why and how marketers have used camels, and left us thirsting for more
Start-up SALT wants to break feminine stereotypes around money, and is asking women to reassert agency
It’s that time of year again when brands suddenly start paying obeisance to women power. From sentimental to ...
Three years after its inception, compliance with GST procedures remains a headache for exporters, job workers ...
Corporate social responsibility (CSR) initiatives of companies are altering the prospects for wooden toys of ...
Aequs Aerospace to create space for large-scale manufacture of toys at Koppal
And it has every reason to smile. Covid-19 has triggered a consumer shift towards branded products as ...
Please Email the Editor